Abstract
Myocardial infarction (MI) is currently one of the most fatal cardiovascular diseases worldwide. The screening, treatment, and prognosis of MI are top priorities for cardiovascular centers globally due to its characteristic occult onset, high lethality, and poor prognosis. MI is caused by coronary artery occlusion induced by coronary atherosclerotic plaque blockage or other factors, leading to ischemic necrosis and apoptosis of cardiomyocytes. Although significant advancements have been made in the study of cardiomyocytes at the cellular and molecular levels, RNA-binding proteins (RBPs) have not been extensively explored in the context of MI. RBPs, as key regulators coordinating cell differentiation and tissue homeostasis, exhibit specific functions in gene transcription, RNA modification and processing, and post-transcriptional gene expression. By binding to their target RNA, RBPs coordinate various RNA dynamics, including cellular metabolism, subcellular localization, and translation efficiency, thereby controlling the expression of encoded proteins. Classical RBPs, including HuR, hnRNPs, and RBM family molecules, have been identified as critical regulators in myocardial hypoxia, oxidative stress, pro-inflammatory responses, and fibrotic repair. These RBPs exert their effects by modulating key pathophysiological pathways in MI, thereby influencing specific cardiac outcomes. Additionally, specific RBPs, such as QKI and fused in sarcoma (FUS), are implicated in the apoptotic pathways activated during MI. This apoptotic pathway represents a significant molecular phenotype in MI, offering novel perspectives and insights for mitigating cardiomyocyte apoptosis and attenuating the progression of MI. Therefore, this review systematically summarizes the role of RBPs in the main pathophysiological stages of MI and explores their potential therapeutic prospects.
Introduction
Myocardial infarction (MI) remains a leading cause of global mortality, characterized by coronary artery occlusion that leads to ischemic necrosis and apoptosis of cardiomyocytes. While advancements in reperfusion therapy have improved survival rates, the subsequent molecular "aftershocks" — including runaway inflammation and pathological fibrosis — often culminate in heart failure. Traditional research has heavily focused on transcription factors as the primary "on/off" switches for gene expression. However, a critical layer of control known as post-transcriptional regulation, mediated by RNA-binding proteins (RBPs), has emerged as a high-leverage "limelight" for therapeutic intervention.
RNA-Binding Proteins: The Master Conductors of Post-Transcriptional Regulation
RBPs are key regulators that coordinate cell differentiation and tissue homeostasis. By binding to target RNA sequences through specific domains (such as Zinc fingers or Cold shock domains), RBPs control the fate of RNA after it is produced but before it is translated into protein. This includes managing splicing, polyadenylation, nucleocytoplasmic transport, localization, stability, and translation efficiency.
As shown in the figure above, RBPs act as dynamic sensors. For instance, under hypoxic stress, proteins like HuR (ELAVL1) translocate from the nucleus to the cytoplasm to stabilize mRNAs like VEGF, which are essential for the heart's adaptive response. This nucleocytoplasmic shuttle allows the cell to rapidly pivot its protein production in response to injury.
Pathophysiological Stages of Myocardial Infarction
The impact of RBPs can be categorized across five major pathophysiological stages of MI:
- Hypoxia/Ischemia: Initial oxygen loss triggers RBP-mediated adaptive responses to preserve cell viability.
- Oxidative Stress: RBPs regulate the damage caused by reactive oxygen species (ROS), with the PTBP1-lncRNA-SNHG8-ALAS2 axis identified as a major regulator of heme synthesis.
- Inflammation: The immune response to tissue damage is tightly controlled by RBP-RNA networks that modulate pro-inflammatory cytokine stability.
- Apoptosis: Programmed cell death pathways, involving RBPs like QKI and FUS, determine the ultimate extent of cardiomyocyte loss.
- Fibrosis: Long-term scarring is driven by RBPs like MBNL1, which transform healthy fibroblasts into scar-producing myofibroblasts.
Key Regulatory Axes and Therapeutic Potential
Recent genome-wide analyses have identified nearly 500 RBPs differentially expressed during myocardial ischemic injury. These proteins often form complex networks with non-coding RNAs. A notable example is the circFndc3b-FUS-VEGF axis, where a circular RNA "sponges" the RBP FUS to prevent it from suppressing vital growth factors.
Furthermore, epitranscriptomic modifications, particularly m6A methylation, play a decisive role. "Writer" proteins like METTL3/14 and "reader" proteins like YTHDF2 control cardiomyocyte survival by determining which damaged RNAs should be degraded and which should be translated.
The therapeutic potential of targeting these interactions is underscored by the clinical success of drugs like Spinraza, which uses antisense oligonucleotides to modulate RBP-RNA interactions. In the context of MI, targeting the HuR-CUGBP1-VEGF-A pathway offers a strategy for revascularizing the infarct border zone, while inhibiting RBPs like PUM2 or QKI could mitigate pathological scarring.
Future Directions and Clinical Challenges
Despite the promise, several challenges remain. The "double-edged sword" nature of RBPs — where a protein might be protective in early ischemia but harmful during chronic fibrosis — requires precise temporal intervention. Additionally, because a single RBP can regulate thousands of genes, future therapies must focus on high-specificity tools like aptamers or targeted nanoparticles to minimize off-target effects. Bridging the "human gap" through large-scale clinical validation of these RBP fluctuations in patients is the next critical step toward clinical application.
Summary updated